Active monitoring versus early treatment for head and neck paragangliomas
Part of Brain & nervous system, Cancer clinical trials.
This study compares two ways of managing head and neck paragangliomas (rare, usually non-cancerous tumors). One group will receive standard care with active monitoring and treatments as needed, while the other group will have more immediate therapeutic interventions. The goal is to see which approach better preserves nerve function and quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a head or neck paraganglioma larger than 10 mm, confirmed by MRI or CT within the last 6 months.
- You do not have nerve palsy (weakness/paralysis) due to the tumor.
- You do not have signs of aggressive tumor (pain, atypical imaging, or suspicious lymph nodes).
- You have not had radiation therapy to the neck for this condition.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study reviews medical records of patients with pheochromocytoma or paraganglioma (rare tumors that produce hormones and can spread) who were treated with a radioactive injection therapy between 2000 and 2024. Researchers want to understand how well this treatment works and its long-term effects.
This study looks at people who have been newly diagnosed with pheochromocytoma/paraganglioma (PPGL), those with a past history of PPGL, or those with genetic risk for it. It may help doctors better evaluate and understand PPGL using specific tests.
This study helps doctors better understand and diagnose pheochromocytoma and paraganglioma—rare tumors that release stress hormones and cause high blood pressure and other symptoms. Researchers will study your medical history, blood and urine tests, imaging scans, and genetic information to improve how these conditions are found and understood.
This study looks at heart and metabolic health in people who have pheochromocytomas or paragangliomas that do not produce extra hormones. It aims to understand whether these 'silent' tumors affect cardiovascular and metabolic health, and how they compare to other cases.
This study follows patients with pheochromocytoma or paraganglioma (rare hormone-producing tumors) who are having surgery. Researchers will monitor your blood pressure closely during and after surgery using continuous monitoring technology and artificial intelligence to better understand and predict blood pressure changes.
This trial tests an oral drug called ONC206 (JZP3507) for people with advanced pheochromocytoma or paraganglioma that cannot be removed with surgery. It may be an option if you've already tried standard treatments or cannot take them.
Hear when a new Paragangliomas trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.